Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of 29.40% is 111% above its 5-year average of -272.89%, near the high end of its 5-year range (-4777.30%–81.32%).
107.44% above its 12-month average of -395.13%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 76.28%.
NET PROFIT MARGIN
29.40%
NET PROFIT MARGIN AVG TTM
-395.13%
NET PROFIT MARGIN AVG 3Y
-250.60%
NET PROFIT MARGIN AVG 5Y
-272.89%
NET PROFIT MARGIN AVG 10Y
-241.23%
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+107.44%
CURRENT VS 3Y AVG
+111.73%
CURRENT VS 5Y AVG
+110.77%
CURRENT VS 10Y AVG
+112.19%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.02%
median of 813 covered companies
CURRENT VS SECTOR MEDIAN
+147100.00%
vs the sector median at left
Protagonist Therapeutics, Inc.
Market Cap
$8.80B
Net Profit Margin
29.40%
TTM Avg
-395.13%
3Y Avg
-250.60%
5Y Avg
-272.89%
Market Cap
$8.68B
Net Profit Margin
-47.79%
TTM Avg
-8441.28%
3Y Avg
-4260.06%
5Y Avg
-2873.03%
Market Cap
$8.97B
Net Profit Margin
-24.68%
TTM Avg
-51.58%
3Y Avg
-141.39%
5Y Avg
-94.26%
Market Cap
$9.02B
Net Profit Margin
-2.03%
TTM Avg
1.55%
3Y Avg
7.31%
5Y Avg
8.11%
Market Cap
$8.57B
Net Profit Margin
-285.41%
TTM Avg
-634.98%
3Y Avg
-446.89%
5Y Avg
-343.19%
Market Cap
$8.40B
Net Profit Margin
3.60%
TTM Avg
-1.75%
3Y Avg
-5.71%
5Y Avg
-20.27%
Market Cap
$9.33B
Net Profit Margin
-2.03%
TTM Avg
1.55%
3Y Avg
7.31%
5Y Avg
8.11%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Protagonist Therapeutics, Inc. (PTGX) | $8.80B | 29.40% | -395.13% | -250.60% | -272.89% |
| Arrowhead Pharmaceuticals, Inc. (ARWR)vs › | $8.68B | -47.79% | -8441.28% | -4260.06% | -2873.03% |
| Axsome Therapeutics, Inc. (AXSM)vs › | $8.97B | -24.68% | -51.58% | -141.39% | -94.26% |
| Bruker Corporation (BRKRP)vs › | $9.02B | -2.03% | 1.55% | 7.31% | 8.11% |
| Kymera Therapeutics, Inc. (KYMR)vs › | $8.57B | -285.41% | -634.98% | -446.89% | -343.19% |
| Oscar Health, Inc. (OSCR)vs › | $8.40B | 3.60% | -1.75% | -5.71% | -20.27% |
| Bruker Corporation (BRKR)vs › | $9.33B | -2.03% | 1.55% | 7.31% | 8.11% |
| Insulet Corp. (PODD)vs › | $9.35B | 12.29% | 14.66% | 10.46% | 7.35% |
| Vaxcyte, Inc. (PCVX)vs › | $9.41B | 0.00% | 0.00% | 0.00% | 0.00% |
| Krystal Biotech, Inc. (KRYS)vs › | $9.55B | 54.82% | 41.66% | 26.22% | 17.48% |
Operating Margin
-343.6%
Net Profit Margin
29.4%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 76.28% |
| 2026-03-31 | 6.71% |
| 2025-12-31 | -596.80% |
| 2025-09-30 | -834.87% |
| 2025-06-30 | -626.96% |
| 2025-03-31 | -41.15% |
| 2024-12-31 | 77.17% |
| 2024-09-30 | -710.37% |
| 2024-06-30 | -734.73% |
| 2024-03-31 | 81.32% |
| 2023-12-31 | 45.56% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | 0.00% |
| 2022-12-31 | 0.00% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | -4777.30% |
| 2022-03-31 | -81.37% |
| 2021-12-31 | -428.30% |
| 2021-09-30 | -328.64% |
| 2021-06-30 | -1361.68% |
| 2021-03-31 | -387.75% |
| 2020-12-31 | -334.27% |
| 2020-09-30 | -59.20% |
| 2020-06-30 | -312.39% |
| 2020-03-31 | -550.59% |
| 2019-12-31 | -643.66% |
| 2019-09-30 | -396.26% |
| 2019-06-30 | 356.26% |
| 2019-03-31 | -904.04% |
| 2018-12-31 | -589.25% |
| 2018-09-30 | -142.80% |
| 2018-06-30 | -74.21% |
| 2018-03-31 | -71.06% |
| 2017-12-31 | -27.05% |
| 2017-09-30 | -54.95% |
| 2017-06-30 | 0.00% |
| 2017-03-31 | 0.00% |
| 2016-12-31 | 0.00% |
| 2016-09-30 | 0.00% |
| 2016-06-30 | 0.00% |
| 2016-03-31 | 0.00% |
| 2015-12-31 | 0.00% |
| 2015-09-30 | 0.00% |
| 2015-06-30 | 0.00% |
| 2015-03-31 | 0.00% |
